{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:15:48Z","timestamp":1784074548955,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T00:00:00Z","timestamp":1623456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.eclinm.2021.100998","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T05:13:25Z","timestamp":1625548405000},"page":"100998","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Applicability of protocols from high-income countries in a resource limited setting; real world data of histopathology, clinical features and long-term outcome of Hodgkin Lymphoma in Sri Lanka"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5439-8398","authenticated-orcid":false,"given":"Saman","family":"Hewamana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakmali","family":"Kandabadage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thurairajah","family":"Skandarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Peiris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobitha","family":"Abeyaratne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gehan","family":"Arseculeratne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eranga","family":"Perera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Harischandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananda","family":"Wijewickrama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gnani","family":"Somasundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadivelu","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surjit","family":"Somiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyankara","family":"Jayawardena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9304-7534","authenticated-orcid":false,"given":"Rohini","family":"Wadanamby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geethani","family":"Galagoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chathuri","family":"Jayasinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandu","family":"De Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeewa","family":"Munasinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bandula","family":"Wijesiriwardena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayantha","family":"Balawardena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2021.100998_bib0001","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00428-013-1442-0","article-title":"Thomas Hodgkin: the \u2018man\u2019 and \u2018his disease\u2019: humani nihil a se alienum putabit (nothing human was foreign to him)","volume":"463","author":"Geller","year":"2013","journal-title":"Virchows Arch"},{"key":"10.1016\/j.eclinm.2021.100998_bib0002","first-page":"252","article-title":"Cancer treatment and survivorship statistics, 2014: cancer treatment and survivorship statistics, 2014","volume":"64","author":"DeSantis","year":"2014","journal-title":"CA A Cancer J Clin"},{"key":"10.1016\/j.eclinm.2021.100998_bib0003","doi-asserted-by":"crossref","first-page":"6400","DOI":"10.1200\/JCO.2005.05.016","article-title":"State-of-the-art therapeutics: Hodgkin's lymphoma","volume":"23","author":"Connors","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2021.100998_bib0004","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.hoc.2007.07.004","article-title":"New strategies for the treatment of advanced-stage Hodgkin's lymphoma","volume":"21","author":"Diehl","year":"2007","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.eclinm.2021.100998_bib0005","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ijc.31096","article-title":"Lower socioeconomic status is independently associated with shorter survival in Hodgkin Lymphoma patients\u2014an analysis from the Brazilian Hodgkin lymphoma registry","volume":"142","author":"Biasoli","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eclinm.2021.100998_bib0006","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/bjh.12878","article-title":"Guidelines for the first line management of classical Hodgkin lymphoma","volume":"166","author":"Follows","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.eclinm.2021.100998_bib0007","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","year":"2017"},{"key":"10.1016\/j.eclinm.2021.100998_bib0008","first-page":"1860","article-title":"Report of the committee on Hodgkin's disease staging classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"key":"10.1016\/j.eclinm.2021.100998_bib0009","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting","volume":"7","author":"Lister","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2021.100998_bib0010","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(02)08272-7","article-title":"Quantification of the completeness of follow-up","volume":"359","author":"Clark","year":"2002","journal-title":"Lancet North Am. Ed."},{"key":"10.1016\/j.eclinm.2021.100998_bib0011","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2021.100998_bib0012","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a Trial of PET-directed therapy for early-stage Hodgkin's Lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2021.100998_bib0013","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT Scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2021.100998_bib0014","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-2257.2005.00736.x","article-title":"Clinico-pathological study of Hodgkin's lymphoma in a cancer center in Taiwan","volume":"27","author":"Lee","year":"2005","journal-title":"Clin Lab Haematol"},{"key":"10.1016\/j.eclinm.2021.100998_bib0015","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0145-2126(01)00126-6","article-title":"Hodgkin's disease in Asians: incidence patterns and risk factors in population-based data","volume":"26","author":"Glaser","year":"2002","journal-title":"Leuk Res"},{"key":"10.1016\/j.eclinm.2021.100998_bib0016","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s12032-011-9902-3","article-title":"Clinical characteristics and prognostic factors in Chinese patients with Hodgkin's lymphoma","volume":"29","author":"Zhu","year":"2012","journal-title":"Med Oncol"},{"key":"10.1016\/j.eclinm.2021.100998_bib0017","doi-asserted-by":"crossref","first-page":"e987","DOI":"10.1097\/MD.0000000000000987","article-title":"Prevalence of common non-hodgkin lymphomas and subtypes of hodgkin lymphoma by nodal site of involvement: a systematic retrospective review of 938 cases","volume":"94","author":"Laurent","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.eclinm.2021.100998_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195629","article-title":"Overview and outcome of Hodgkin's Lymphoma: experience of a single developing country's oncology centre","volume":"13","author":"Shamoon","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.eclinm.2021.100998_bib0019","first-page":"651","article-title":"Hodgkin's lymphoma in Pakistan: a clinico-epidemiological study of 658 cases at a cancer center in Lahore","volume":"7","author":"Siddiqui","year":"2006","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.eclinm.2021.100998_bib0020","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/oxfordjournals.epirev.a036276","article-title":"Epidemiology of Hodgkin's disease","volume":"6","author":"Grufferman","year":"1984","journal-title":"Epidemiol Rev"},{"key":"10.1016\/j.eclinm.2021.100998_bib0021","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/725219","article-title":"Incidence patterns and outcomes for Hodgkin lymphoma patients in the United States","volume":"2011","author":"Shenoy","year":"2011","journal-title":"Adv Hematol"},{"key":"10.1016\/j.eclinm.2021.100998_bib0022","first-page":"252","article-title":"Cancer treatment and survivorship statistics, 2014: cancer treatment and survivorship statistics, 2014","volume":"64","author":"DeSantis","year":"2014","journal-title":"CA A Cancer J Clin"},{"key":"10.1016\/j.eclinm.2021.100998_bib0023","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4103\/0971-5851.171550","article-title":"Clinical profile and outcome of adult Hodgkin lymphoma: experience from a tertiary care institution","volume":"36","author":"Maddi","year":"2015","journal-title":"Indian J Med Paediatr Oncol"},{"key":"10.1016\/j.eclinm.2021.100998_bib0024","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00277-011-1262-8","article-title":"Hodgkin's lymphoma\u2013long-term outcome: an experience from a tertiary care cancer center in North India","volume":"90","author":"Ganesan","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.eclinm.2021.100998_bib0025","doi-asserted-by":"crossref","first-page":"881","DOI":"10.7326\/0003-4819-73-6-881","article-title":"Combination chemotherapy in the treatment of advanced Hodgkin's disease","volume":"73","author":"Devita","year":"1970","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eclinm.2021.100998_bib0026","first-page":"325","article-title":"High frequency of primary refractory disease and low progression-free survival rate of Hodgkin's lymphoma: a decade of experience in a Latin American center","volume":"39","author":"Jaime-P\u00e9rez","year":"2017"},{"key":"10.1016\/j.eclinm.2021.100998_bib0027","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1200\/JCO.2015.62.2860","article-title":"Global health equity: cancer care outcome disparities in High-, Middle-, and Low-Income Countries","volume":"34","author":"De Souza","year":"2016","journal-title":"JCO"},{"key":"10.1016\/j.eclinm.2021.100998_bib0028","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1200\/JCO.2004.01.021","article-title":"Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?","volume":"22","author":"Laskar","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2021.100998_bib0029","first-page":"466","article-title":"[A analysis of the outcome and prognostic factors in 415 patients with Hodgkin lymphoma]","volume":"37","author":"Tao","year":"2015","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"10.1016\/j.eclinm.2021.100998_bib0030","unstructured":"\"World Economic Outlook Database, April 2021\". World Economic Outlook. International Monetary Fund. April 2021. Retrieved 7 April 2021."},{"key":"10.1016\/j.eclinm.2021.100998_bib0031","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1080\/10428190802663205","article-title":"How much does it cost to treat children with Hodgkin lymphoma in Africa?","volume":"50","author":"Stefan","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.eclinm.2021.100998_bib0032","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2147\/CEOR.S178649","article-title":"Real-world analysis of cost, health care resource utilization, and supportive care in Hodgkin lymphoma patients with frontline failure","volume":"10","author":"Bonafede","year":"2018","journal-title":"CEOR"},{"key":"10.1016\/j.eclinm.2021.100998_bib0033","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/annonc\/mdl397","article-title":"ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors","volume":"18","author":"Boleti","year":"2007","journal-title":"Ann Oncol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537021002789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537021002789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T19:08:24Z","timestamp":1762888104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537021002789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":33,"alternative-id":["S2589537021002789"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2021.100998","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Applicability of protocols from high-income countries in a resource limited setting; real world data of histopathology, clinical features and long-term outcome of Hodgkin Lymphoma in Sri Lanka","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2021.100998","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100998"}}